Pipeline: nab-sirolimus

Home Pipeline
PopulationsPhase 1 Phase 2ApprovedCurrent Status
precision-logoAdvanced Malignant PEComa

nab-sirolimus

 
  • First FDA approved therapy for advanced malignant PEComa
  • Based on Ph 2 Registrational AMPECT Trial
Advanced or recurrent endometrioid-type endometrial cancer

nab-sirolimus + letrozole

 
  • Open-label study currently enrolling patients
  • Initial data expected in 2024
DrugStageCurrent Status
precision-logoAdvanced Malignant PEComa nab-sirolimus Approved
  • First FDA approved therapy for advanced malignant PEComa
  • Based on Ph 2 Registrational AMPECT Trial
Advanced or recurrent endometrioid-type endometrial cancer nab-sirolimus + letrozole Phase 2
  • Open-label study currently enrolling patients
  • Initial data expected in 2024